Information  X 
Enter a valid email address

Novacyt S.A. (NCYT)

  Print      Mail a friend

Friday 14 February, 2020

Novacyt S.A.

Update on CE Mark Approved coronavirus test

RNS Number : 1076D
Novacyt S.A.
14 February 2020
 

Novacyt S.A.

 

("Novacyt", the "Company" or the "Group")

 

Update on CE Mark Approved coronavirus test

 

Paris, France and Camberley, UK - 14 February 2020 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, is pleased to announce that, further to its announcement on 7 February 2020, its subsidiary, Primerdesign Limited, is on schedule to launch a CE-Mark approved nCoV test in the week commencing 17 February 2020.  The Primerdesign website has commenced taking orders for the CE-marked test ahead of the planned launch next week.

 

 

- End -

 

Contacts

Novacyt SA

Graham Mullis, Chief Executive Officer

Anthony Dyer, Chief Financial Officer

+44 (0)1276 600081

 

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

 

FTI Consulting (International)

Victoria Foster Mitchell/Mary Whittow

+44 (0)20 3727 1000

[email protected] / [email protected]

 

FTI Consulting (France)

Arnaud de Cheffontaines / Astrid Villette

+33 (0)147 03 69 47 / +33 (0)147 03 69 51

[email protected] / [email protected]

 

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests.  Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

 

For more information please refer to the website: www.novacyt.com

 

About 2019-nCoV

Researchers at the Chinese Centre for Disease Control and Prevention and their collaborators have sequenced the 2019 novel coronavirus (2019-nCoV) pathogen from patient samples and have found it to be genetically distinct from the severe acute respiratory syndrome (SARS) virus that caused an epidemic in 2002 and 2003, as well as from the Middle East respiratory syndrome (MERS) virus that was detected in 2012. 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCEZLFFBLLFBBZ

a d v e r t i s e m e n t